HBK Investments’s RAPT Therapeutics RAPT Stock Holding History

HBK Investments’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,000	Closed	-$258K	–	754
2020 Q3	$258K	Buy	+1,000	New	+$222K	﹤0.01%	577

Other funds holding RAPT

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KXA

KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ROTUOC

Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

HBK Investments's RAPT Position: Q4 2020 in Review

HBK Investments sold out of RAPT Therapeutics (RAPT) in Q4 2020, closing a stake of 1,000 shares — an estimated $258K sold.

HBK Investments first reported a position in RAPT in Q3 2020 and held it in 1 quarter. The position peaked at $258K in Q3 2020. 81 funds tracked by Wall St. Rank hold RAPT as of Q4 2020.

HBK Investments reported no remaining RAPT Therapeutics position as of Q4 2020 after selling out during the quarter.
HBK Investments sold 1,000 RAPT Therapeutics shares in Q4 2020, an estimated $258K.
HBK Investments first reported a position in RAPT Therapeutics in Q3 2020 and held it in 1 quarter.
HBK Investments's RAPT Therapeutics position peaked at $258K in Q3 2020.
81 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2020.

Based on HBK Investments's 13F filing for Q4 2020, filed 16 Feb 2021.